Results 131 to 140 of about 46,848 (253)
Neuropsychopharmacology Reports, Volume 46, Issue 2, June 2026.In a Japanese patient with schizophrenia, the effects of repeated smoking and quitting cigarettes on plasma concentrations of clozapine (CLZ) and its major metabolites, N‐desmethyl clozapine (NCLZ) and N‐oxide clozapine (OCLZ), were shown to be reproducible. ABSTRACT Clozapine (CLZ) is used for treatment‐resistant schizophrenia.
Kazuro Ikawa +3 more
wiley +1 more source
Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.This graphical summary illustrates the efficacy and safety of brexpiprazole (2–4 mg) in patients with schizophrenia. The meta‐analysis demonstrates significant improvement in clinical outcomes, with reductions in Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression ‐ Severity scale (CGI‐S) scores, indicating better symptom ...
Sher Bano +14 more
wiley +1 more source
CAT‐Hokkaido: A tablet‐based assessment of cognitive impairment in schizophrenia
Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.CAT‐Hokkaido is a brief tablet‐based cognitive assessment covering six neurocognitive domains relevant to schizophrenia. In patients with schizophrenia, it detected deficits in four of six tasks and showed significant correlations with corresponding MCCB measures, supporting its potential utility in assessing cognitive impairment.
Atsuhito Toyomaki +5 more
wiley +1 more source
Blonanserin transdermal patch for treating delirium: A case series
Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.In a retrospective case series of 51 patients with delirium treated at a single center between 2020 and 2022, clinical improvement was observed in 84.3% of patients following the use of a blonanserin transdermal patch, often within 1–2 weeks. The patch was mainly selected for patients who had difficulty taking oral medications.
Mari Hemmi +9 more
wiley +1 more source
Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.Current bladder cancer therapies can cause toxicity and bladder dysfunction. Brief intravesical‐like aripiprazole exposure reduced bladder cancer cell viability and was associated with redox stress and caspase‐3 activation, while ex vivo findings suggested preserved bladder structure and function, warranting further investigation as a potential ...
Liam A. O'Callaghan +3 more
wiley +1 more source
Forget community care - reinstitutionalisation is here [PDF]
, 2002 Priebe, S, Turner, T
core +1 more source
Cost-Offsets of New Medications for Treatment of Schizophrenia [PDF]
Broad claims are frequently made that new medications will offset all or part of their costs by reducing other areas of Medicaid spending. In this paper we examine the net impact on spending for new drugs used to treat schizophrenia.
Richard G. Frank +2 more
core
Gerodontology, Volume 43, Issue 2, Page 272-275, June 2026.ABSTRACT Introduction Burning mouth syndrome (BMS) is occasionally accompanied by denture intolerance. Case Presentation An 80‐year‐old woman with complaints of residual and relapsed intraoral pain and denture intolerance due to BMS was improved by olanzapine without severe adverse events, and her eating ability was successfully restored.
Motoko Watanabe +7 more
wiley +1 more source
Phenol Neurolysis in Pain and Palliative Medicine
Pain Practice, Volume 26, Issue 5, June 2026.ABSTRACT Background Pain is a common symptom in palliative care and affects patients' quality of life considerably. Standard analgesics are sometimes insufficient and are associated with substantial side effects. Neurolysis, the targeted destruction of nerves using thermal or chemical agents, offers an additional option for managing localized pain in ...
Jeroen H. A. Creemers +6 more
wiley +1 more source